|Rapid Review Complete
|For the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended at the submitted price
Approved following confidential price negotiation for lenalidomide across all licensed indications (January 2018).